Overview

Zanubrutinib Followed Zanubrutinib Plus FCR (Fludarabine Cyclophosphamide and Rituximab) / Zanubrutinib Plus BR(Bendamustine and Rituximab) in Newly Diagnosed Symptomatic CLL/SLL

Status:
Not yet recruiting

Trial end date:
2024-11-29

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the long-term efficacy of BTK inhibitor Zanubrutinib monotherapy , sequential Zanubrutinib combined (Fludarabine, cyclophosphamide and rituximab /bendamustine and rituximab)FCR/BR regimen by a limited period of treatment for the newly diagnosed Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The investigators propose this combination will improve the MRD negative rate of patients with CR/CRi after treatment was significantly higher than that of FCR chemotherapy can be a time-limited regimen which will reduce the life-time therapy and benefit the patients.

Phase:

Phase 2

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital

Treatments:

Bendamustine Hydrochloride
Cyclophosphamide
Fludarabine
Rituximab
Zanubrutinib